Age-Adjusted ESR Upper Limit of Normal
Calculates age-adjusted upper limit of normal for Erythrocyte Sedimentation Rate (ESR). Rule: Male = age/2; Female = (age + 10)/2. Useful for PMR, GCA, and other inflammatory conditions where absolute ESR value may be misleading without age context.
Score interpretation
ESR within age-adjusted normal range
→ ESR within expected range for age; if clinical concern for inflammatory disease persists, check CRP and other markers; ESR may be normal in early disease
ESR mildly elevated above age-adjusted ULN
→ Consider inflammatory, infectious, or neoplastic causes; correlate with CRP; repeat in 2–4 weeks if no clear cause; check FBC, LFTs, renal function, protein electrophoresis if persistent elevation
ESR markedly elevated — significant inflammation or serious pathology
→ Consider PMR/GCA (ESR >50 in >70y), sepsis, multiple myeloma, malignancy, SLE, vasculitis; urgent blood tests: FBC, CRP, protein electrophoresis, urine Bence-Jones protein, cultures; consider urgent rheumatology or haematology referral
Interpretation bands for the Age-Adjusted ESR. Apply clinical judgement and local guidance.
References
- Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J. 1983;286(6361):266.
Related
Curated clinical cross-links plus same-class fallbacks.
- Colchicine (Pericarditis / Post-MI Inflammation) · Pericarditis / Coronary Inflammation
- Dexamethasone · Corticosteroid — ENT Inflammation / Croup
- Normal immunoglobulin (IVIG / SCIG) · Pooled human immunoglobulin
- Difluprednate 0.05% Eye Drops · Potent Ophthalmic Corticosteroid — Uveitis / Post-Operative Inflammation
- Lidocaine Tumescent Solution (Liposuction/Infiltration) · Local Anaesthetic — Superdilute Tumescent Infiltration
- Dupilumab (Moderate-Severe Asthma) · Anti-IL-4/IL-13 receptor alpha monoclonal antibody (type 2 inflammation biologic)
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.